2 / 24
Page 44
Notes:
Journal of Pharmaceutical care and Health Systems | ISSN: 2376-0419 | Volume 5
Pharmaceutical sciences
11
th
World Congress on
September 28-29, 2018 | Montreal, Canada
Development and evaluation of co-polymeric carrier system of Riserdronate for the treatment of
Osteoporosis
Supriya Verma
Panjab University, India
Aim:
The study was intended to develop a copolymer based carrier system of drug Risedronate (RIS) for its effective bone
delivery at the target site for the treatment of Osteoporosis (porous bone disease).
Summary of The Problem:
Risedronate is a FDA-approved third-generation bisphosphonate drug which acts as an
antiresorptive agent in the treatment of Osteoporosis. It is a versatile drug molecule, which has been used for the treatment of
postmenopausal Osteoporosis, glucocorticoid-induced Osteoporosis, male Osteoporosis and Paget’s disease. It is available in
the market as oral tablet dosage forms but has some challenges like patience in compliance, low drug permeability and is prone
to metal chelation, which leads to GIT irritation.
Methodology & Theoretical Orientation:
The chosen drug (RIS) was entrapped in a copolymer based carrier system, which
consists of chitosan, tripolyphosphate (TPP) and eudragit. Chitosan and eudragit copolymer based nanoparticles were prepared
by using ionic gelation followed by the coacervation method
Observations:
The prepared system has been characterized by particles size, PDI, zeta potential and entrapment efficiency,
which were found as 272.8 nm, 0.184, 17.9 mV and 77.05 % respectively. FTIR studies proved the user interaction of the drug
with the polymeric shells of the system. Moreover, it’s
in vitro
release has been carried out in various pHmedia, i.e., 1.2, 6.8 and
7.4 and was found tremendously better than the conventional system. In ovariectomized rat (
in vivo
) model, its efficiency and
safety were proved 7 times and 10 times of the conventional system respectively. Moreover, the formulation was found stable
for the period of six months.
Summary & Conclusion:
Hence, this is a simple, commercial and easy to scale up method for the preparation of novel drug
delivery based nanoparticle system of our choice of drug, i.e., Risedronate
Biography
Supriya Verma has been engaged in experimental laboratory work that includes formulation development,
in vitro
characterization and
in vivo
evaluation of the
novel drug delivery based formulations i.e., liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, etc. Her area of research is based on the
systematic design and development of the nanostructured delivery system of Aceclofenac and Risedronate. In the last four years of research experience, she has
got wonderful exposure on topical and oral drug delivery systems in an industry (Panacea Biotech, Lalru) as well as in an academic institute (University Institute
of Pharmaceutical Sciences, Panjab University, Chandigarh). She has not only involved in the research but also undertaking the teaching of Undergraduate and
Postgraduate classes. Moreover, she is having collaboration with medical institutes i.e., PGIMER, Chandigarh and AIIMS, New Delhi for the assistance of clinical
studies over there. Also, she is writing research articles and book chapters related to her professional domain. She has attended various National as well as
International level conferences and been awarded with six best paper awards in the last four years.
Supriya Verma, J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C3-033